Eutilex.Co.,Ltd (KOSDAQ:263050)
South Korea · Delayed Price · Currency is KRW 959.00
+221.00 (29.95%)
At close: Feb 6, 2026
Eutilex.Co.,Ltd Revenue
In the year 2025, Eutilex.Co.,Ltd had annual revenue of 10.29B KRW with 8.06% growth. Eutilex.Co.,Ltd had revenue of 2.39B in the quarter ending December 31, 2025, a decrease of -9.37%.
Revenue
10.29B
Revenue Growth
+8.06%
P/S Ratio
3.43
Revenue / Employee
n/a
Employees
n/a
Market Cap
35.32B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 10.29B | 768.30M | 8.06% |
| Dec 31, 2024 | 9.53B | 9.39B | 7,136.10% |
| Dec 31, 2023 | 131.65M | -84.01M | -38.95% |
| Dec 31, 2022 | 215.66M | 142.12M | 193.25% |
| Dec 31, 2021 | 73.54M | -1.96B | -96.39% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| J2KBIO | 32.97B |
| NGeneBio | 21.24B |
| ADBiotech | 12.90B |
| MOA Life Plus | 11.22B |
| EyeGene | 3.57B |
| Poongjeon Pharmacy CO.,LTD. | 1.54B |
| Kainos Medicine | 1.17B |
| Epibiotech | 449.62M |